MyMD Pharmaceuticals Performance
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
The company secures a Beta (Market Risk) of -0.64, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning MyMD Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, MyMD Pharmaceuticals is likely to outperform the market. MyMD Pharmaceuticals right now secures a risk of 0.0%. Please verify MyMD Pharmaceuticals potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if MyMD Pharmaceuticals will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MyMD Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, MyMD Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 749.1 K |
MyMD |
MyMD Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 182.00 in MyMD Pharmaceuticals on September 26, 2024 and sell it today you would earn a total of 0.00 from holding MyMD Pharmaceuticals or generate 0.0% return on investment over 90 days. MyMD Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than MyMD, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MyMD Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MyMD Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MyMD Pharmaceuticals, and traders can use it to determine the average amount a MyMD Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MYMD |
Based on monthly moving average MyMD Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MyMD Pharmaceuticals by adding MyMD Pharmaceuticals to a well-diversified portfolio.
MyMD Pharmaceuticals Fundamentals Growth
MyMD Stock prices reflect investors' perceptions of the future prospects and financial health of MyMD Pharmaceuticals, and MyMD Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MyMD Stock performance.
| Return On Equity | -1.01 | |||
| Return On Asset | -0.5 | |||
| Current Valuation | 2.99 M | |||
| Shares Outstanding | 2.37 M | |||
| Price To Book | 0.46 X | |||
| EBITDA | (17.12 M) | |||
| Cash And Equivalents | 5.62 M | |||
| Cash Per Share | 0.15 X | |||
| Total Debt | 48.87 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 4.54 X | |||
| Cash Flow From Operations | (12.98 M) | |||
| Earnings Per Share | (9.27) X | |||
| Total Asset | 17.86 M | |||
| Retained Earnings | (101.98 M) | |||
About MyMD Pharmaceuticals Performance
By analyzing MyMD Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into MyMD Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MyMD Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MyMD Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company was founded in 2014 and is headquartered in Baltimore, Maryland. Mymd Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Things to note about MyMD Pharmaceuticals performance evaluation
Checking the ongoing alerts about MyMD Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MyMD Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MyMD Pharmaceuticals is now traded under the symbol TNFA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| MyMD Pharmaceuticals is not yet fully synchronised with the market data | |
| MyMD Pharmaceuticals may become a speculative penny stock | |
| MyMD Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (4 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MyMD Pharmaceuticals currently holds about 5.62 M in cash with (12.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. |
- Analyzing MyMD Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MyMD Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining MyMD Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MyMD Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MyMD Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MyMD Pharmaceuticals' stock. These opinions can provide insight into MyMD Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |